Myeloid neoplasms with eosinophilia

Blood

Volumn 129, Issue 6, 2017, Pages 704-714

  Reiter, Andreas ^a   Gotlib, Jason ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSCRIPTION FACTOR ETV6; ABELSON KINASE; ANTINEOPLASTIC AGENT; FGFR1 PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; ONCOPROTEIN; PDGFRB PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ACUTE LEUKEMIA; CANCER PROGNOSIS; CLONAL VARIATION; CYTOGENETICS; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FUSION GENE; GRANULOCYTIC SARCOMA; HUMAN; HYPEREOSINOPHILIA; LYMPHOMA; MUTATION; MYELOBLAST; MYELODYSPLASTIC SYNDROME; MYELOID NEOPLASM; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REVIEW; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA; METABOLISM; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; EOSINOPHILIA; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPEREOSINOPHILIC SYNDROME; JANUS KINASE 2; LEUKEMIA; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 85015294920     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-10-695973     Document Type: Review

References (103)

1. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130(3): 607-612.
2. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med. 1968;68(6): 1220-1229.
3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54(1): 1-27.
4. Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338(22): 1592-1600.
5. Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5(2): 157-176.
6. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010; 85(2): 158-164.
7. Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330(8): 535-538.
8. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999; 341(15): 1112-1120.
9. Bain BJ, Gilliland DG, Horny H-P, et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 68-73
10. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20): 2391-2405.
11. Bain BJ, Gilliland DG, Horny H-P. et al. Chronic eosinophilic leukaemia, not otherwise specified. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 51-53.
12. Schwaab J, Jawhar M, Naumann N, et al. Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation. Ann Hematol. 2016;95(4): 557-562.
13. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101(12): 4660-4666.
14. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104(10): 3038-3045.
15. Maric I, Robyn J, Metcalfe DD, et al. KIT D816Vassociated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-Associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007;120(3): 680-687.
16. Schwaab J, Umbach R, Metzgeroth G, et al. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol. 2015;90(9): 774-777.
17. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003;27(10): 883-885.
18. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7): 2366-2372.
19. Lasho TL, Finke CM, Zblewski D, et al. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer J. 2015;5: e275.
20. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 2001; 3(5): 9.
21. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002; 359(9317): 1577-1578.
22. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26(9): 881-884.
23. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13): 1201-1214.
24. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA. 2003; 100(13): 7830-7835.
25. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102(9): 3093-3096.
26. Lambert F, Heimann P, Herens C, Chariot A, Bours V. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. J Mol Diagn. 2007;9(3): 414-419.
27. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-Associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6): 1183-1188.
28. Elling C, Erben P, Walz C, et al. Novel imatinibsensitive PDGFRA-Activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood. 2011;117(10): 2935-2943.
29. Jovanovic JV, Score J, Waghorn K, et al. Lowdose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109(11): 4635-4640.
30. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9): 1173-1179.
31. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004; 103(2): 473-478.
32. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6): 1319-1325.
33. Helbig G, Moskwa A, Hus M, et al. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript-results of Polish multicentre study. Hematol Oncol. 2010; 28(2): 93-97.
34. Pardanani A, D'Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A. Long-Term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia. 2012;26(11): 2439-2441.
35. Legrand F, Renneville A, Macintyre E, et al; on behalf of the French Eosinophil Network. The spectrum of FIP1L1-PDGFRA-Associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine (Baltimore). 2013;92(5): e1-e9.
36. Helbig G, Stella-Holowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRAexpressing patients. Br J Haematol. 2008; 141(2): 200-204.
37. Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007;110(10): 3552-3556.
38. Helbig G, Kyrcz-Krzemién S. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Am J Hematol. 2014;89(1): 115.
39. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia. 2005;19(2): 286-287.
40. Ohnishi H, Kandabashi K, Maeda Y, Kawamura M, Watanabe T. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol. 2006;134(5): 547-549.
41. Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009;23(5): 845-851.
42. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7): 2332-2338.
43. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003; 3(5): 459-469.
44. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood. 2006;108(4): 1374-1376.
45. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005; 106(9): 3206-3213.
46. von Bubnoff N, Gorantla SP, Thöne S, Peschel C, Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood. 2006; 107(12): 4970-4971.
47. Metzgeroth G, Erben P, Martin H, et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia. 2012;26(1): 162-164.
48. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77(2): 307-316.
49. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol. 2002;107(2): 113-122.
50. Ross TS, Gilliland DG. Transforming properties of the Huntingtin interacting protein 1/plateletderived growth factor beta receptor fusion protein. J Biol Chem. 1999;274(32): 22328-22336.
51. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347(7): 481-487.
52. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable longterm remissions with imatinib. Blood. 2014; 123(23): 3574-3577.
53. Savage N, George TI, Gotlib J. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. Int J Lab Hematol. 2013;35(5): 491-500.
54. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998;18(1): 84-87.
55. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-Associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood. 2000;95(5): 1788-1796.
56. Popovici C, Zhang B, Gregoire M-J, et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood. 1999;93(4): 1381-1389.
57. Smedley D, Demiroglu A, Abdul-Rauf M, et al. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia. 1999;1(4): 349-355.
58. Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001; 98(13): 3778-3783.
59. Roumiantsev S, Krause DS, Neumann CA, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004;5(3): 287-298.
60. Pini M, Gottardi E, Scaravaglio P, et al. A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. Hematol J. 2002;3(6): 315-316.
61. Mozziconacci MJ, Carbuccia N, Prebet T, et al. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature. Leuk Res. 2008;32(8): 1304-1308.
62. Vizmanos JL, Hernández R, Vidal MJ, et al. Clinical variability of patients with the t(6;8)(q27; p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J. 2004;5(6): 534-537.
63. Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101(40): 14479-14484.
64. Chase A, Bryant C, Score J, Cross NC. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica. 2013;98(1): 103-106.
65. Khodadoust MS, Luo B, Medeiros BC, et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia. 2016;30(4): 947-950.
66. Kreil S, Ades L, Bommer M, et al. Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes [abstract]. Blood. 2015;126(23). Abstract 2812.
67. Reiter A, Walz C, Watmore A, et al. The t(8;9) (p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65(7): 2662-2667.
68. Murati A, Gelsi-Boyer V, Adélaïde J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia. 2005;19(9): 1692-1696.
69. Bousquet M, Quelen C, De Mas V, et al. The t(8;9) (p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005;24(48): 7248-7252.
70. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-Associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90(7): 2535-2540.
71. Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities Br J Haematol. 2014;166(6): 809-817.
72. Griesinger F, Hennig H, Hillmer F, et al. A BCRJAK2 fusion gene as the result of a t(9;22)(p24; q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer. 2005;44(3): 329-333.
73. Cirmena G, Aliano S, Fugazza G, et al. A BCRJAK2 fusion gene as the result of a t(9;22)(p24; q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183(2): 105-108.
74. He R, Greipp PT, Rangan A, et al. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. Cancer Genet. 2016; 209(5): 223-228.
75. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-And lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17(18): 5321-5333.
76. Carron C, Cormier F, Janin A, et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood. 2000;95(12): 3891-3899.
77. Duployez N, Nibourel O, Ducourneau B, et al. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript. Eur J Haematol. 2016;97(4): 399-402.
78. Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood. 2012;120(7): 1529-1531.
79. Rumi E, Milosevic JD, Casetti I, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013;31(17): e269-e271.
80. Rumi E, Milosevic JD, Selleslag D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015;94(11): 1927-1928.
81. Schwaab J, Knut M, Haferlach C, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCRJAK2 fusion genes. Ann Hematol. 2015;94(2): 233-238.
82. Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15(13): 4263-4269.
83. Vu HA, Xinh PT, Masuda M, et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia. 2006;20(8): 1414-1421.
84. Falchi L, Mehrotra M, Newberry KJ, et al. ETV6-FLT3 fusion gene-positive, eosinophiliaassociated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014; 28(10): 2090-2092.
85. Walz C, Erben P, Ritter M, et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood. 2011;118(8): 2239-2242.
86. Chonabayashi K, Hishizawa M, Matsui M, et al. Successful allogeneic stem cell transplantation with long-Term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia. Ann Hematol. 2014;93(3): 535-537.
87. Hosseini N, Craddock KJ, Salehirad S, et al. ETV6/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia. J Hematop. 2014;7(2): 71-77.
88. Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol. 2007;35(11): 1723-1727.
89. Troadec E, Dobbelstein S, Bertrand P, et al. A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3 [published online ahead of print 2 December 2016] Leukemia. doi: 10.1038/leu.2016.304.
90. Van Limbergen H, Beverloo HB, van Drunen E, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer. 2001;30(3): 274-282.
91. Kelly JC, Shahbazi N, Scheerle J, et al. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet. 2009;192(1): 36-39.
92. Gancheva K, Virchis A, Howard-Reeves J, et al. Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review. Mol Cytogenet. 2013;6(1): 39.
93. Tirado CA, Siangchin K, Shabsovich DS, Sharifian M, Schiller G. A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature. Biomark Res. 2016;4(1): 16.
94. Zaliova M, Moorman AV, Cazzaniga G, et al. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica. 2016;101(9): 1082-1093.
95. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107(2): 101-107.
96. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008;119(4): 199-206.
97. Metzgeroth G, Schwaab J, Gosenca D, et al. Long-Term follow-up of treatment with imatinib in eosinophilia-Associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013;27(11): 2254-2256.
98. Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L. alpha-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood. 1995;85(8): 2284-2285.
99. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-A in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol. 1998;58(2): 137-141.
100. Helbig G, Stella-Holowiecka B, Majewski M, Lewandowska M, Holowiecki J. Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation. Haematologica. 2007;92(11): e118-e119.
101. Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemién S. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol. 2012;87(6): 643-645.
102. Pardanani A, Lasho T, Wassie E, et al. Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia. 2016;30(9): 1924-1926.
103. Wang SA, Tam W, Tsai AG, et al. Targeted nextgeneration sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29(8): 854-864.